High-level ciprofloxacin resistance from point mutations in gyrA and parC confined to global hospital-adapted clonal lineage CC17 of Enterococcus faecium

被引:83
作者
Leavis, HL [1 ]
Willems, RJL [1 ]
Top, J [1 ]
Bonten, MJM [1 ]
机构
[1] Univ Utrecht, Ctr Med, Eijkman Winkler Inst Microbiol, Dept Internal Med, NL-3584 CX Utrecht, Netherlands
关键词
D O I
10.1128/JCM.44.3.1059-1064.2006
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
To substantiate a common genetic background of ciprofloxacin-resistant Enterococcus faecium, 32 ciprofloxacin-resistant (Cip(r)) and 31 ciprofloxacin-susceptible (Cip(s)) isolates from outbreaks, clinical infections, surveillances, and animals from 10 different countries were genotyped by multilocus sequence typing. Additionally, susceptibilities to ampicillin and vancomycin and the presence of esp were determined and the quinolone resistance-determining regions of parC, gyrA, parB, and gyrE were sequenced. High-level Cipr (MIC >= 64 mu g/ml) due to point mutations in the quinolone resistance-determining region was unique to a distinct hospital-adapted genetic complex in E. faecium, previously designated CC17. Low-level Cip(r) (MIC = 4 mu g/ml) in non-CC17 strains is not attributable to point mutations in any subunit of the topoisomerase genes, and the mechanism of resistance remains unclear. Acquisition of mutations in parC and gyrA, leading to high-level Cip(r) is, in addition to ampicillin resistance and the presence of a putative pathogenicity island, another cumulative step in hospital adaptation of CC17.
引用
收藏
页码:1059 / 1064
页数:6
相关论文
共 62 条
[11]   DETECTION OF GLYCOPEPTIDE RESISTANCE GENOTYPES AND IDENTIFICATION TO THE SPECIES LEVEL OF CLINICALLY RELEVANT ENTEROCOCCI BY PCR [J].
DUTKAMALEN, S ;
EVERS, S ;
COURVALIN, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (01) :24-27
[12]   Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium [J].
El Amin, N ;
Jalal, S ;
Wretlind, B .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) :947-949
[13]  
*EU ANT RES SURV S, 2005, 2003 EARSS
[14]   eBURST: Inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data [J].
Feil, EJ ;
Li, BC ;
Aanensen, DM ;
Hanage, WP ;
Spratt, BG .
JOURNAL OF BACTERIOLOGY, 2004, 186 (05) :1518-1530
[15]   Risk factors associated with ampicillin resistance in patients with bacteraemia caused by Enterococcus faecium [J].
Fortún, J ;
Coque, TM ;
Martín-Dávila, P ;
Moreno, L ;
Cantón, R ;
Loza, E ;
Baquero, F ;
Moreno, S .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (06) :1003-1009
[16]   Primary targets of fluoroquinolones in Streptococcus pneumoniae [J].
Fukuda, H ;
Hiramatsu, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :410-412
[17]   National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992-April 2000, issued June 2000 [J].
Gerberding, J ;
Gaynes, R ;
Horan, T ;
Alonso-Echanove, J ;
Edwards, J ;
Emori, G ;
Fridkin, S ;
Hageman, J ;
Henderson, T ;
Lawton, R ;
Peavy, G ;
Richards, C ;
Tolson, J ;
Wages, J .
AMERICAN JOURNAL OF INFECTION CONTROL, 2000, 28 (06) :429-448
[18]   European survey of vancomycin-resistant enterococci in at-risk hospital wards and in vitro susceptibility testing of ramoplanin against these isolates [J].
Goossens, H ;
Jabes, D ;
Rossi, R ;
Lammens, C ;
Privitera, G ;
Courvalin, P .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 :5-12
[19]   In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones [J].
Grohs, P ;
Houssaye, S ;
Aubert, A ;
Gutmann, L ;
Varon, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) :3542-3547
[20]   MUTATIONS IN THE GYRA GENE OF A HIGHLY FLUOROQUINOLONE-RESISTANT CLINICAL ISOLATE OF ESCHERICHIA-COLI [J].
HEISIG, P ;
SCHEDLETZKY, H ;
FALKENSTEINPAUL, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (04) :696-701